- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02733874
A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.
A multi-center, randomized, single blind, positive controlled trials that assess the effectiveness, safety and cost-effectiveness analysis in patients with mild to moderate psoriasis vulgaris and compare Compound Clobetasol Propionate Ointment to Calcipotriol Betamethasone Ointment.
Objectives of Study:
- Compare Compound Clobetasol Propionate Ointment to Calcipotriol Betamethasone Ointment in the treatment of mild to moderate psoriasis vulgaris in effectiveness and safety;
- Compare the cost-effectiveness analysis of two treatment programs.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The informed consent has been signed in;
- Patients who were 18~65 years of age, stable psoriasis patients, the gender is not limited;
- The lesion area does not exceed 10% of the total surface area of the body;
- The overall evaluation of the researchers (Physician Global Assessment,PGA) greater than or equal to 2;
- The observation of target lesions of minimum diameter greater than or equal to 2cm.
Exclusion Criteria:
- Patients who have known or been doubted of being allergic to the composition of the drug;
- Patients who were diagnosed as non-psoriasis vulgaris (such as erythrodermic type, pustular psoriasis, arthritis), and developing psoriasis vulgaris;
- Patients who have illnesses in severe central nervous system, cardiovascular system, kidney, liver, digestive tract, respiratory system, metabolism and skeletal muscle system and mental disorders;
- Patients with other diseases may affect the assessment of efficacy, such as eczema, etc.;
- Liver functions(such as Alanine aminotransferase, Aspartate transaminase) is 2 times greater than(or equal to) the upper limit of normal value, or renal functions (such as creatinine) is 1.5 times greater than(or equal to) the upper limit of normal value;
- Patients with hypercalcemia whose serum calcium values exceed the upper limit of the normal value or patients who were suspected of having a disease of hypercalcemia;
- Patients who are taking drugs that affect metabolism of calcium. Drugs that increase the serum calcium values: agents containing calcium, active vitamin D3 medication, injection, anabolic agents (ipriflavone preparations); Drugs that decrease the serum calcium values: calcitonin preparation, double phosphate ester compound preparation, sex hormone preparations).
- Patients who were randomly divided into groups had received systemic biological treatment (listed or unlisted), such as: ustekinumab treatment accepted by patients after the past 12 weeks, infliximab, adalimumab treatment accepted by patients after the past 8 weeks, infliximab, etanercept treatment accepted by patients after the past 4 weeks accepted and so on;
- Patients who have accepted non-abiotic systemic therapy that may have an effect on psoriasis, including but not limited to vitamin A preparations, cortical hormone, vitamin D analogs, immunosuppressant, compound glycyrrhizin, traditional Chinese medicine and so on after the past 4 weeks of random entry or test period.
- Patients who have were accepted psoralen ultraviolet A(PUVA) treatment after the past 4 weeks of random entry or test period.
- Patients who have accepted ultraviolet therapy or partial treatments of psoriasis drugs after the past 2 weeks of random entry or test period;
- Patients who have used concomitant drugs recently in the past 2 weeks after random entry or plan to use concomitant drugs during test period, such as Beta blockers, anti malaria drugs, lithium preparations, etc.;
- Patients who have accepted other clinical trials after the the last 4 weeks of random entry;
- Patients who work outside for a long time with sun exposure may have an impact on the diagnosis and treatment of the disease.
- Women of lactation, pregnancy and childbearing age who refuse to accept effective contraceptive measures.
- Patients who have known or been suspected of non-compliance, such as alcoholism, drug dependence or mental illness, etc, and can not be suitable to the clinical trials judged by the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: test group
Compound Clobetasol Propionate Ointment
|
|
Active Comparator: control group
Calcipotriol Betamethasone Ointment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The improvement of psoriasis area and severity index scores(PASI scores)
Time Frame: At baseline, 2 weeks and 4 weeks after baseline.
|
The improvement of psoriasis area and severity index scores(PASI scores) are a system that assesses the damage of psoriasis severity and treatment response .
The system is used to classify and evaluate according to the severity of lesions, areas of skin lesion and body surface area ratio of various body parts.
|
At baseline, 2 weeks and 4 weeks after baseline.
|
The overall evaluation of the researchers (Physician Global Assessment,PGA)
Time Frame: At baseline, 2 weeks and 4 weeks after baseline.
|
On every visiting viewpoint , researchers give a mark of the infiltration / hypertrophy (I), erythema (E) and scales (s) according to the level.PGA scores are acquired by the average of above three kinds of scores.
|
At baseline, 2 weeks and 4 weeks after baseline.
|
The Symptom score reduce index (SSRI)
Time Frame: 4 weeks after baseline.
|
1)According to the improvement of psoriasis area and severity index scores(PASI scores) before and after treatments, the symptom score reduce index (SSRI) was calculated. 2)The symptom score reduce index (SSRI) = (the PASI scores before treatment - the PASI scores after treatment) / the PASI scores before treatment x 100% |
4 weeks after baseline.
|
Efficiency of treatment
Time Frame: 4 weeks after baseline.
|
1)Healing patients : SSRI ≥ 90%, Marked effectiveness patients : 60% < SSRI < 90%, Improvement patients : 20% < SSRI < 60%, ineffectiveness patients :SSRI < 20%. 2)Efficiency of treatment = (The number of healing patients + The number of markedly effective patients + The number of improved patients ) / total number of patients in this group x 100% |
4 weeks after baseline.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Healing rate
Time Frame: 4 weeks after treatment
|
1)Healing patients : SSRI ≥ 90%, Marked effectiveness patients : 60% < SSRI < 90%, Improvement patients : 20% < SSRI < 60%, ineffectiveness patients :SSRI < 20%. 2)Healing rate = The number of healing patients / total number of patients in this group x 100% |
4 weeks after treatment
|
Markedly effective rate
Time Frame: 4 weeks after treatment
|
1)Healing patients : SSRI ≥ 90%, Marked effectiveness patients : 60% < SSRI < 90%, Improvement patients : 20% < SSRI < 60%, ineffectiveness patients :SSRI < 20%. 2)Markedly effective rate = The number of markedly effective patients / total number of patients in this group x 100% |
4 weeks after treatment
|
Response rate of PASI (PASI 75) after the treatment of 4 weeks
Time Frame: 4 weeks after treatment
|
Response rate of PASI (PASI 75) after the treatment of 4 weeks = The number of patients whose SSRI are more than 75% / total number of patients x 100%
|
4 weeks after treatment
|
Response rate of PGA ( basic fading rate of PGA) after the treatment of 4 weeks
Time Frame: 4 weeks after treatment
|
Response rate of PGA ( basic fading rate of PGA) after the treatment of 4 weeks:patients with 1 score of PGA for the last time/ total number of patients in this group x 100%
|
4 weeks after treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZY2015001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Compound Clobetasol Propionate Ointment
-
LEO PharmaCompletedPsoriasis VulgarisFrance
-
Galderma R&DCompletedPlaque PsoriasisUnited States
-
Oslo University HospitalPhotocureCompletedGenital Lichen PlanusNorway
-
Medstar Health Research InstituteCompletedVulvar Lichen SclerosusUnited States
-
Mahidol UniversityCompleted
-
BayerTerminated
-
Medstar Health Research InstitutePatty Brisben Foundation For Women's Sexual Health; Society of Gynecologic...RecruitingFractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus (VULVIE)Vulvar Lichen SclerosusUnited States
-
Padagis LLCCompleted
-
Galderma R&DCompletedPlaque PsoriasisUnited States, Canada
-
LEO PharmaCompletedConnective Tissue Diseases | Skin Tissue DiseasesGermany